top of page
Nelson Advisors > European HealthTech & MedTech


The Scaleup Europe Fund: Navigating Late Stage Growth Capital Opportunities for European HealthTech and MedTech Companies
Despite Europe's thriving startup ecosystem, which consistently produces world-class scientific discoveries and breakthrough technologies, innovative enterprises face severe challenges when attempting to scale within the continent. As tech and life science companies transition from early-stage validation to the capital-intensive scaleup phase, they routinely encounter an underdeveloped late-stage venture capital sector. This domestic funding gap, particularly acute in growth
Nelson Advisors
Jun 25


How could the Software sell off and AI bubble in early 2026 affect Digital Health, HealthTech and MedTech funding and M&A for the rest of 2026?
The global financial landscape in the first quarter of 2026 underwent a profound transformation, characterised by an aggressive re-rating of software valuations and a critical interrogation of the artificial intelligence investment cycle. By late February 2026, the North American Tech Software Index had declined approximately 30% from its mid-September 2025 peak, a volatility primarily driven by the emergence of autonomous "agentic" tools capable of automating high-level cogn
Nelson Advisors
Feb 26


HealthTech and MedTech Mergers and Acquisitions Predictions for 2026
The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions.
This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat
Nelson Advisors
Nov 10, 2025


HealthTech and MedTech IPO predictions 2026
The Initial Public Offering (IPO) landscape for the HealthTech and MedTech sectors is projected to undergo a significant recovery in 2026. Following a period of volatility and retrenchment between 2022 and 2024, the confluence of stabilising macroeconomic conditions, investor appetite for disruptive technology and a substantial backlog of highly mature companies suggests that 2026 will be the most active year for public offerings since the market peaks of 2021.
Nelson Advisors
Oct 18, 2025


The Symbiotic Relationship Between MedTech and DefenceTech
The relationship between medical technology (MedTech) and defence technology has historically been characterised by an ad hoc, one-directional flow of innovation, often described as a "spin-out" effect where military research unexpectedly finds civilian applications. However, a contemporary analysis reveals a more complex, mutually beneficial, and increasingly institutionalized symbiosis. This interdependence is no longer a matter of serendipitous discovery but a deliberate,
Nelson Advisors
Sep 10, 2025
bottom of page